Werewolf Therapeutics Inc (HOWL)vsVertex Pharmaceuticals Inc (VRTX)
HOWL
Werewolf Therapeutics Inc
$1.07
+1.90%
HEALTHCARE · Cap: $47.93M
VRTX
Vertex Pharmaceuticals Inc
$549.04
+3.44%
HEALTHCARE · Cap: $141.65B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 59839% more annual revenue ($12.59B vs $21.00M). VRTX leads profitability with a 35.0% profit margin vs -164.8%. VRTX earns a higher WallStSmart Score of 62/100 (C+).
HOWL
Avoid31
out of 100
Grade: F
VRTX
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+85.7%
Fair Value
$4.68
Current Price
$1.07
$3.61 discount
Margin of Safety
+41.3%
Fair Value
$952.30
Current Price
$549.04
$403.26 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 40.6%
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -461.1% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : HOWL
The strongest argument for HOWL centers on Operating Margin.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : HOWL
The primary concerns for HOWL are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
HOWL profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
HOWL carries more volatility with a beta of 0.51 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (62/100 vs 31/100), backed by strong 35.0% margins and 12.5% revenue growth. HOWL offers better value entry with a 85.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Werewolf Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?